Literature DB >> 11587246

Hot flashes: aetiology and management.

D Barton1, C Loprinzi, D Wahner-Roedler.   

Abstract

Menopause, an event often accompanied by symptoms such as hot flashes, can have a significant impact on a woman's quality of life. A majority of women will experience hot flashes at some point in their life, given a normal life span. Despite multiple theories, the exact pathophysiology of hot flashes is not yet known. Many types of treatment options exist for women with hot flashes, from hormonal and nonhormonal pharmacological therapies to nonpharmacological interventions. Choosing the best treatment option for specific women involves knowledge of the risks and benefits of each treatment. Hormones (estrogen and/or progesterone, or tibolone alone) are still the most effective option available, resulting in an 80 to 90% reduction in hot flashes. The best nonhormonal treatment to date is in the class of newer antidepressants that comprises various selective reuptake inhibitors; for example, venlafaxine provides about a 60% reduction in hot flashes. This article provides evidence-based information about available treatment options for hot flash management, with special consideration of populations such as breast cancer survivors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587246     DOI: 10.2165/00002512-200118080-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  79 in total

1.  Concentrations of calcitonin gene-related peptide and neuropeptide Y in plasma increase during flushes in postmenopausal women.

Authors:  Y A Wyon; A C Spetz; G E Theodorsson; M L Hammar
Journal:  Menopause       Date:  2000 Jan-Feb       Impact factor: 2.953

2.  Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Ogen/Provera Study Group.

Authors:  S L Nand; M A Webster; R Baber; G Z Heller
Journal:  Climacteric       Date:  1998-09       Impact factor: 3.005

3.  A double-blind trial with clonidine and a placebo to treat hot flushes.

Authors:  B G Wren; L B Brown
Journal:  Med J Aust       Date:  1986-03-31       Impact factor: 7.738

4.  Use of medroxyprogesterone acetate to prevent menopausal symptoms.

Authors:  J L Bullock; F M Massey; R D Gambrell
Journal:  Obstet Gynecol       Date:  1975-08       Impact factor: 7.661

5.  Megestrol acetate: phase II study of a single daily administration in advanced breast cancer.

Authors:  P Pronzato; F Brema; D Amoroso; G Bertelli; P F Conte; M C Martini; G Pastorino; R Rosso
Journal:  Breast Cancer Res Treat       Date:  1990-11       Impact factor: 4.872

6.  Definitions of hot flashes in breast cancer survivors.

Authors:  G Finck; D L Barton; C L Loprinzi; S K Quella; J A Sloan
Journal:  J Pain Symptom Manage       Date:  1998-11       Impact factor: 3.612

7.  Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes.

Authors:  R R Freedman
Journal:  Fertil Steril       Date:  1998-08       Impact factor: 7.329

8.  Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment.

Authors:  P Vercellini; N Vendola; A Colombo; C Passadore; L Trespidi; P G Crosignani
Journal:  Gynecol Obstet Invest       Date:  1992       Impact factor: 2.031

9.  A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms.

Authors:  M Hammar; S Christau; J Nathorst-Böös; T Rud; K Garre
Journal:  Br J Obstet Gynaecol       Date:  1998-08

10.  Postmenopausal hot flushes: a disorder of thermoregulation.

Authors:  I V Tataryn; P Lomax; J G Bajorek; W Chesarek; D R Meldrum; H L Judd
Journal:  Maturitas       Date:  1980-07       Impact factor: 4.342

View more
  6 in total

1.  Acupuncture for hot flashes in patients with prostate cancer.

Authors:  Tomasz M Beer; Maria Benavides; Sandra L Emmons; Margaret Hayes; Guohui Liu; Mark Garzotto; Deirdre Donovan; Nina Katovic; Caron Reeder; Kristine Eilers
Journal:  Urology       Date:  2010-05-21       Impact factor: 2.649

2.  Resistance training reduced luteinising hormone levels in postmenopausal women in a substudy of a randomised controlled clinical trial: A clue to how resistance training reduced vasomotor symptoms.

Authors:  Sigrid Nilsson; Moa Henriksson; Emilia Berin; David Engblom; Anna-Clara Spetz Holm; Mats Hammar
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

Review 3.  Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause.

Authors:  Claudio N Soares; Jennifer R Poitras; Jennifer Prouty
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

4.  Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions.

Authors:  Deirdre R Pachman; Jason M Jones; Charles L Loprinzi
Journal:  Int J Womens Health       Date:  2010-08-09

Review 5.  Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability?

Authors:  Claudio N Soares; Brook Zitek
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

6.  The Beneficial and Adverse Effects of Raloxifene in Menopausal Women: A Mini Review.

Authors:  Imaneh Khorsand; Reyhaneh Kashef; Masumeh Ghazanfarpour; Elaheh Mansouri; Sareh Dashti; Talat Khadivzadeh
Journal:  J Menopausal Med       Date:  2018-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.